indication

Insulin Resistance

Competitive landscape

as of 2026-07-01
Competitive set
3
2 approved · 1 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
27 events
2018
2020
2022
2024
2026
2028
2030
2032
2034
2036
2038
2040
2042
today
focal launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Aripiprazole
US-approved 2002 · ABILIFY
Phase 41 trial
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2041
drugCompleted
Olanzapine
US-approved 1996 · ZYPREXA Intramuscular
—1 trial
OwnerEli Lilly and Company
Protection2041
drugCompleted
Amisulpride
Investigational
—1 trial
OwnerShanghai Mental Health Center
Protection2038

Market size

prevalence as a range, not a number